{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:58:50Z","timestamp":1761821930924,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","revespcardiol.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.rec.2019.03.008","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T01:44:13Z","timestamp":1557971053000},"page":"968-970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Initial Real-World Experience With PCSK-9 Inhibitors in Current Indications for Reimbursement in Spain"],"prefix":"10.1016","volume":"72","author":[{"given":"Alberto","family":"Cordero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"F\u00e1cila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mois\u00e9s","family":"Rodr\u00edguez-Ma\u00f1ero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel J.","family":"G\u00f3mez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Bertomeu-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose R.","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2019.03.008_bib0030","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2019.03.008_bib0035","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2019.03.008_bib0040","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2019.03.008_bib0045","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.recesp.2018.06.005","article-title":"PCSK9 Inhibitors: From Innovation to Sustainable Clinical Application","volume":"71","author":"Lekuona","year":"2018","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2019.03.008_bib0050","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.recesp.2018.02.013","article-title":"Cost-effectiveness and Budget Impact of Treatment With Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain","volume":"71","author":"Olry de Labry Lima","year":"2018","journal-title":"Rev Esp Cardiol."}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585719301033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585719301033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:57:02Z","timestamp":1761821822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585719301033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":5,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1885585719301033"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2019.03.008","relation":{},"ISSN":["1885-5857"],"issn-type":[{"type":"print","value":"1885-5857"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial Real-World Experience With PCSK-9 Inhibitors in Current Indications for Reimbursement in Spain","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}